MigVax
Blood & Organ Banks · Israel · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Tarshish St, Qiryat Shmona, Hazafon, 110...Phone Number
+972 46953511Website
www.migvax.comRevenue
$13.8 MillionIndustry
About MigVax
MigVax Ltd. is focused on developing an innovative oral subunit vaccine for COVID-19, known as MigVax-101, which utilizes a chimeric protein to elicit comprehensive immune responses. This vaccine aims to simplify administration by dissolving on the tongue, eliminating the need for healthcare professionals, and is stable at room temperature for two months. Targeting a wide range of clients, including pediatric, adolescent, and pregnant populations, MigVax addresses logistical challenges associated with current injectable vaccines. The company employs advanced analytical techniques, including an Artificial Neural Network, to predict future variants and enhance vaccine efficacy.Explore more
MigVax Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
MigVax Tech Stack
A closer look at the technologies used by MigVax
Top Blood & Organ Banks Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MigVax
Sign Up For FreeTo access detailed company insights
MigVax Ltd. is focused on developing an innovative oral subunit vaccine for COVID-19, known as MigVax-101, which utilizes a chimeric protein to elicit comprehensive immune responses. This vaccine aims to simplify administration by dissolving on the tongue, eliminating the need for healthcare professionals, and is stable at room temperature for two... Read More
